Skip to main content
OpenTrials
Completed

NCT Number: NCT02618720

Intravenous Versus Combined Oral and Intravenous Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Elective Colorectal Surgery

To assess the effects of a combined antimicrobial prophylaxis using oral ornidazole (the day before surgery) and intravenous cephalosporin (before surgical incision) with that of intravenous cephalosporin alone (standard of care) in combination with oral placebo on the incidence of SSI within 30 days after elective colorectal surgery.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 3

Primary location

CHU Clermont-Ferrand

Clermont-Ferrand, 63003, France

About this study

Surgical site infection (SSI) is a major cause of nosocomial infection in surgical patients, with the highest rates being reported (ranging from 15% to 30%) in colorectal surgery. SSI is an independent predictor of postoperative mortality and is associated with longer hospital stay, a 5-fold likelihood of postoperative readmission and a 2- to 3-fold increase in costs of care. Given the high prevalence and financial burden associated with SSI, American and European guidelines have been issued providing evidenced-based recommendations for the prevention of postoperative SSI. However, the prevalence of SSI remains high despite adherence to these guidelines and the application of evidence-based preventive measures.

Risk factors for SSI, whether modifiable or not, are mainly related to the patient condition (including age, severe comorbidity, diabetes, nutritional status, steroid use, smoking, and immunosuppression) and/or the surgical procedure (especially the surgical duration and skin disinfection). The prevention of SSI consists of several individual measures, and antibiotic prophylaxis covering aerobic and anaerobic bacteria is highly recommended in patients scheduled to elective colorectal resection, with French and European guidelines recommending the administration of intravenous cephalosporin within 30 minutes before surgical incision.

Recent data from retrospective studies and two meta-analyses of clinical trials provided compelling arguments that oral antibiotic administration before surgery in addition to conventional intravenous prophylaxis may be useful in further reducing by almost 75% the incidence of SSI (relative risk 0.55 [CI95%: 0.41 to 0.74]) after elective colorectal cancer surgery.

However, most of these studies have limitations precluding extrapolation of data into routine care, especially:

  • prolonged duration of intravenous antibiotic administration, which is no longer recommended in elective surgery;
  • the use of antibiotics for oral prophylaxis whose availability is limited;
  • only a few studies focused specifically on colorectal resection;
  • most studies did not include enhanced recovery after surgery (ERAS) programs, which was found to improve outcome following colorectal surgery, and
  • most studies have used mechanical bowel preparation, which is no longer recommended in colonic surgery while the issue still remains open for rectal surgery.

Investigators hypothesized that oral antibiotic prophylaxis using ornidazole, which has a spectrum of activity extended to most anaerobic bacteria and whose pharmacokinetic profile allows a single administration the day before surgery, in addition to intravenous antibiotic prophylaxis could be more effective than intravenous antibiotic prophylaxis alone using cephalosporin in reducing the incidence of SSI after elective colorectal surgery. Given the number of patients operated of colorectal surgery each year, the study is of significant clinical importance

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age > 18
  • Laparoscopic or non-laparoscopic elective colorectal surgery

Exclusion criteria

  • Non elective colorectal surgery (emergent surgery and/or reintervention or revision of a previous colorectal procedure)
  • Significant concomitant surgical procedure (e.g., liver resection for metastasis)
  • Bacterial infection at the time of surgery or antimicrobial therapy up to 2 weeks before surgery
  • Inflammatory bowel disease
  • Severe obesity (defined as a BMI >35 kg/m2)
  • Known history of hypersensitivity to β-lactams and imidazoles
  • Preoperative severe impairment in renal function (creatinine clearance (MDRD) < 30 ml/min)
  • Patients with known colonization with multidrug-resistant digestive bacteria, especially multidrug-resistant gram-negative bacteria (requiring specific infection control measures)
  • Allergy to lactose, galactose intolerance, Lapp lactase deficiency or glucose/galactose malabsorption (rare metabolic disease)
  • Pregnant women, breastfeeding women, women of childbearing age without effective contraceptive- Refusal to participate or inability to provide informed consent

Treatment and study plan

Ornidazole

Drug

Placebo

Drug

Primary outcomes

  1. occurrence of any SSI within 30 days after surgery.

    Time frame: 30 days after surgery

    The primary end point of the trial is the occurrence of any SSI within 30 days after surgery. SSI will be classified as superficial, deep and/or organ-space infection according to validated and well-defined criteria developed by the Centers for Disease Control and Prevention (CDC).

Secondary outcomes

  1. Incidence of individual types of SSI according to the group of treatment

    Time frame: 30 days after surgery

    Incidence of individual types of SSI (superficial incision infection, deep incision infection and organ-space infection) according to the group of treatment, 30 days after surgery

  2. Number of postoperative complications

    Time frame: 30 days after surgery

    Using the Dindo and Clavien classification

  3. Number of surgical complications: anastomotic leakage and the need for abdominal reoperation and/or radiological intervention

    Time frame: 30 days after surgery

  4. Duration of hospital stay

    Time frame: 30 days after surgery

    Including hospital stay of patients who are readmitted after surgery

  5. All-cause mortality

    Time frame: 30 days after surgery

  6. All-cause mortality

    Time frame: 90 days after surgery

  7. Time to introduction of adjuvant chemotherapy related to SSI

    Time frame: 30 days after surgery

  8. Postoperative syndrome of systemic inflammatory response (Infectious complications)

    Time frame: 30 days after surgery

    Number of Postoperative syndrome of systemic inflammatory responses, in each group

  9. Sepsis (Infectious complications)

    Time frame: 30 days after surgery

    Number of Sepsis, in each group

  10. Septic shock (Infectious complications)

    Time frame: 30 days after surgery

    Number of Septic shocks, in each group

  11. Arrhythmia (Cardiovascular complications)

    Time frame: 30 days after surgery

    Number of arrhythmias, in each group

  12. Myocardial infarction (Cardiovascular complications)

    Time frame: 30 days after surgery

    Number of myocardial infarctions, in each group

  13. Acute cardiac failure (Cardiovascular complications)

    Time frame: 30 days after surgery

    Number of acute cardiac failures, in each group

  14. Pneumonia (Respiratory complications)

    Time frame: 30 days after surgery

    Number of pneumonias, in each group

  15. Need for postoperative reventilation (Respiratory complications)

    Time frame: 30 days after surgery

    Number of postoperative reventilations (intubation and/or non-invasive mechanical ventilation), in each group

  16. Renal dysfunction

    Time frame: 30 days after surgery

    Number of Renal dysfunctions in each group. Defined according to the Kidney Disease: Improving Global Outcomes (KDIGO) classification

  17. Time to initiation of adjuvant chemotherapy

    Time frame: 30 days after surgery

    Comparaison of time to initiation of adjuvant chemotherapy between the 2 groups

  18. Need for hospital readmission

    Time frame: 30 days after surgery

    Number of hospital readmissions, in each group

  19. Unexpected admission to intensive care unit

    Time frame: 30 days after surgery

    Number of Unexpected admissions to intensive care unit, in each group

  20. Hospital free days

    Time frame: 30 days after surgery

Sponsors and collaborators

Lead sponsor

University Hospital, Clermont-Ferrand

Other

Registry information

Official study title

Intravenous Versus Combined Oral and Intravenous Antimicrobial Prophylaxis for the Prevention of Surgical Site Infection in Elective Colorectal Surgery: A Double-blinded Multicenter Prospective Randomized Controlled Trial

Acronym: COMBINE

Important dates

Study start
2016
Primary completion
2019
Study completion
2020
First posted
Dec 1, 2015
Registry last updated
Apr 21, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.